ArticleCancer discovery2022
C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan.
Article in Cancer discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed.
- Implications of Palliative Care Screening in Outpatient Comprehensive Cancer Genome Profiling Tests.JMA journal · 2025Trial
- Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Distinct Clinicogenomic Contexts of BRAF-Altered Gliomas and Glioneuronal Tumors: A Nationwide Real-World Study.Cancer science · 2026Article
- Association of TP53 Truncating Mutations with Time to Treatment Failure after First-Line Chemoimmunotherapy in HER2-Mutant Non-Small Cell Lung Cancer.Targeted oncology · 2026Article
- Observed ALK fusion/rearrangement frequency across comprehensive genomic profiling platforms in Japanese routine oncology practice.International journal of clinical oncology · 2026Article
- Facility-level JSMO specialist availability and reconstructable treatment-process measures in colorectal cancer using C-CAT data.International journal of clinical oncology · 2026Article
- Utilization, Reimbursement, and Barriers to Accessing Sequencing Tests for Cancer Care in the Asia-Pacific Region: KSMO Initiatives to Address Cancer Care Inequity.Cancer research and treatment · 2026Article
- Germline pathogenic variants in Japanese adolescents and young adults with advanced solid tumors: a nationwide tumor-normal paired sequencing study.International journal of clinical oncology · 2026Observational
- Comprehensive Genomic Profiling Beyond Driver Testing in Non-Squamous Non-Small Cell Lung Cancer With Known Drivers.Cancer science · 2026Article
- Real-World Testing Landscape and Costs of Companion Diagnostics and Comprehensive Genomic Profiling Across Nine Solid Tumors in Japan: A 10-Year Analysis.Oncology and therapy · 2026Article
- Tumor-Agnostic and Histology-Tuned Targeted Therapies in Gastrointestinal Cancers: NTRK and RET Fusions and the Evolving Role of Molecular Basket Strategies.Journal of gastrointestinal cancer · 2026Review
- Landscape of cancer genomics and precision oncology in Japan, South Korea, China, and Australia.The Lancet regional health. Western Pacific · 2026Review
- Prevalence and complementary distribution of FGFR3 alterations and ERBB2 amplification in metastatic urothelial carcinoma: a nationwide registry analysis.International journal of clinical oncology · 2026Article
- TERT Promoter Mutations Are Preferentially Associated With the ERBB2 G776-Altered Subtype of HER2-Mutant NSCLC.Cancer science · 2026Article
- MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy.Cancer science · 2026Review
- Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis.Current oncology (Toronto, Ont.) · 2026Article
- Comprehensive genomic profiling and tumor mutational burden in parathyroid carcinoma: a nationwide real-world study from Japan.Endocrine · 2026Article
- Facility-Level Availability of Japanese Society of Medical Oncology Specialists and Recorded First-Line Treatment-Process Duration in Pancreatic Cancer: A Nationwide Center for Cancer Genomics and Advanced Therapeutics Registry Analysis.Current oncology (Toronto, Ont.) · 2026Article
- Nationwide genomic data analysis of central nervous system tumors in Japan based on C-CAT database.International journal of clinical oncology · 2026Article
- Tumor Cell Count and Total Cell Count as Surrogate Indicators of Comprehensive Genomic Profiling Success in Pancreatic Cancer Specimens Collected by Endoscopic Ultrasonography-Guided Tissue Acquisition.Journal of hepato-biliary-pancreatic sciences · 2026Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
summarySince June 2019, under the umbrella of the national health insurance system, Japan has started cancer genomic medicine (CGM) with comprehensive genomic profiling (CGP) tests. The Ministry of Health, Labour and Welfare (MHLW) of Japan constructed a network of CGM hospitals (a total of 233 institutes as of July 1, 2022) and established the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), the national datacenter for CGM. Clinical information and genomic data from the CGP tests are securely transferred to C-CAT, which then generates "C-CAT Findings" reports containing information of clinical annotation and matched clinical trials based on the CGP data. As of June 30, 2022, a total of 36,340 datapoints of clinical/genomic information are aggregated in C-CAT, and the number is expected to increase swiftly. The data are now open for sharing with not only the CGM hospitals but also other academic institutions and industries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.